Cardiology/Vascular Diseases | IND Enabling Drugs

Vectura Ltd

Virtual Booth Expert and Agile CDMO Partner for tailor-made solutions.

United Kingdom

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Vectura Signs Agreement with Aerami Therapeutics Inc

Lead Product(s): Imatinib

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Aerami

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 08, 2020

Details:

Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology.

Inositec AG

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001

Lead Product(s): INS-3001

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

U.S. patent number covers specifically the composition of matter and use of inositol derivatives for conditions related to pathological calcium crystallization.

Matinas BioPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Matinas BioPharma Announces Proposed Public Offering of Common Stock

Lead Product(s): MAT9001

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: BTIG

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: IPO January 09, 2020

Details:

Matinas BioPharma anticipates using the net proceeds from the offering primarily for ongoing development for its product candidates, namely MAT9001, and its lipid nano-crystal (“LNC”) platform delivery technology

Find

Find FDA Investigational New Drug (IND) Submissions for Cardiology/Vascular Diseases

IND Enabling

Product Type

Companies

Vectura Ltd

Vectura Signs Agreement with Aerami Therapeutics Inc

Inositec AG

Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001

Matinas BioPharma

Matinas BioPharma Announces Proposed Public Offering of Common Stock